|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sauer R, Becker H, Hohenberger W, Rödel C,
Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF,
et al: Preoperative versus postoperative chemoradiotherapy for
rectal cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Benson AB, Venook AP, Al-Hawary MM, Arain
MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D,
Garrido-Laguna I, et al: NCCN guidelines insights: Rectal cancer,
version 6.2020. J Natl Compr Canc Netw. 18:806–815. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rallis KS, Lai Yau TH and Sideris M:
Chemoradiotherapy in cancer treatment: Rationale and clinical
applications. Anticancer Res. 41:1–7. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tatekawa S, Shimamoto S, Miyata Y, Yoshino
Y, Hirata T, Tamari K, Seo Y, Isohashi F, Yamamoto Y, Uno A, et al:
Monitoring expiratory carbon monoxide to study the effect of
complete smoking cessation on definitive radiation therapy for
early stage glottic carcinoma. Acta Oncol. 60:582–588. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lerman J, Hennequin C, Etienney I,
Abramowitz L, Goujon G, Gornet JM, Guillerm S, Aparicio T, Valverde
A, Cattan P and Quéro L: Impact of tobacco smoking on the patient's
outcome after (chemo)radiotherapy for anal cancer. Eur J Cancer.
141:143–151. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Japanese Society for Cancer of the Colon
and Rectum, . Japanese classification of colorectal, appendiceal,
and anal carcinoma: The 3d English edition [secondary publication].
J Anus Rectum Colon. 3:175–195. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deveci SE, Deveci F, Açik Y and Ozan AT:
The measurement of exhaled carbon monoxide in healthy smokers and
non-smokers. Respir Med. 98:551–556. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nordsmark M and Overgaard J: Tumor hypoxia
is independent of hemoglobin and prognostic for loco-regional tumor
control after primary radiotherapy in advanced head and neck
cancer. Acta Oncol. 43:396–403. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Browman GP, Wong G, Hodson I, Sathya J,
Russell R, McAlpine L, Skingley P and Levine MN: Influence of
cigarette smoking on the efficacy of radiation therapy in head and
neck cancer. N Engl J Med. 328:159–163. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Akagi T, Inomata M, Fujishima H, Fukuda M,
Konishi T, Tsukamoto S, Teraishi F, Ozawa H, Tanaka K, Hida K, et
al: Preoperative chemoradiotherapy versus surgery alone for
advanced low rectal cancer: A large multicenter cohort study in
Japan. Surg Today. 50:1507–1514. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huh JW, Kim HR and Kim YJ: Clinical
prediction of pathological complete response after preoperative
chemoradiotherapy for rectal cancer. Dis Colon Rectum. 56:698–703.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Maas M, Nelemans PJ, Valentini V, Das P,
Rödel C, Kuo LJ, Calvo FA, García-Aguilar J, Glynne-Jones R,
Haustermans K, et al: Long-term outcome in patients with a
pathological complete response after chemoradiation for rectal
cancer: A pooled analysis of individual patient data. Lancet Oncol.
11:835–844. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sadahiro S, Suzuki T, Tanaka A, Okada K,
Saito G, Kamijo A, Akiba T and Kawada S: Phase II study of
preoperative concurrent chemoradiotherapy with S-1 plus bevacizumab
for locally advanced resectable rectal adenocarcinoma. Oncology.
88:49–56. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tomono A, Yamashita K, Kanemitsu K, Sumi
Y, Yamamoto M, Kanaji S, Imanishi T, Nakamura T, Suzuki S, Tanaka K
and Kakeji Y: Prognostic significance of pathological response to
preoperative chemoradiotherapy in patients with locally advanced
rectal cancer. Int J Clin Oncol. 21:344–349. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garland ML, Vather R, Bunkley N, Pearse M
and Bissett IP: Clinical tumour size and nodal status predict
pathologic complete response following neoadjuvant
chemoradiotherapy for rectal cancer. Int J Colorectal Dis.
29:301–307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang CM, Huang CW, Ma CJ, Yeh YS, Su WC,
Chang TK, Tsai HL, Juo SH, Huang MY and Wang JY: Predictive value
of FOLFOX-based regimen, long interval, hemoglobin levels and
clinical negative nodal status, and postchemoradiotherapy CEA
levels for pathological complete response in patients with locally
advanced rectal cancer after neoadjuvant chemoradiotherapy. J
Oncol. 2020:94376842020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Al-Sukhni E, Attwood K, Mattson DM,
Gabriel E and Nurkin SJ: Predictors of pathologic complete response
following neoadjuvant chemoradiotherapy for rectal cancer. Ann Surg
Oncol. 23:1177–1186. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Berardi R, Braconi C, Mantello G,
Scartozzi M, Del Prete S, Luppi G, Martinelli R, Fumagalli M,
Valeri G, Bearzi I, et al: Anemia may influence the outcome of
patients undergoing neo-adjuvant treatment of rectal cancer. Ann
Oncol. 17:1661–1664. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Conroy T, Bosset JF, Etienne PL, Rio E,
François É, Mesgouez-Nebout N, Vendrely V, Artignan X, Bouché O,
Gargot D, et al: Neoadjuvant chemotherapy with FOLFIRINOX and
preoperative chemoradiotherapy for patients with locally advanced
rectal cancer (UNICANCER-PRODIGE 23): A multicentre, randomised,
open-label, phase 3 trial. Lancet Oncol. 22:702–715. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Asoglu O, Bulut A, Aliyev V, Piozzi GN,
Guven K, Bakır B and Goksel S: Chemoradiation and consolidation
chemotherapy for rectal cancer provides a high rate of organ
preservation with a very good long-term oncological outcome: A
single-center cohort series. World J Surg Oncol. 20:3582022.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Asoglu O, Goksoy B, Aliyev V, Mustafayev
TZ, Atalar B, Bakir B, Guven K, Demir G and Goksel S: Watch and
wait strategy for rectal cancer: How long should we wait for a
clinical complete response? Surg Technol Int. 40:130–139. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Aliyev V, Goksel S, Bakir B, Guven K and
Asoglu O: Sphincter-saving robotic total mesorectal excision
provides better mesorectal specimen and good oncological local
control compared with laparoscopic total mesorectal excision in
male patients with mid-low rectal cancer. Surg Technol Int.
38:160–166. 2021.PubMed/NCBI
|
|
24
|
Aliyev V, Piozzi GN, Shadmanov N, Guven K,
Bakır B, Goksel S and Asoglu O: Robotic and laparoscopic
sphincter-saving resections have similar peri-operative,
oncological and functional outcomes in female patients with rectal
cancer. Updates Surg. 75:2201–2209. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aliyev V, Piozzi GN, Huseynov E,
Mustafayev TZ, Kayku V, Goksel S and Asoglu O: Robotic male and
laparoscopic female sphincter-preserving total mesorectal excision
of mid-low rectal cancer share similar specimen quality,
complication rates and long-term oncological outcomes. J Robot
Surg. 17:1637–1644. 2023. View Article : Google Scholar : PubMed/NCBI
|
